Briumvi
Briumvi
BRIUMVI (ublituximab-xiiy) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Administration Information
Briumvi is the anti-CD20 therapy that is administered as a twice yearly 1 hour infusion (after 2 initial loading doses)
Number of yearly treatments: 4
Potential Side Effects
Potential side effects: Most common adverse reactions (greater than/equal to 10%) were infusion reactions such as pyrexia, chills, headache, flu-like illness, tachycardia, nausea, throat irriation, erythema and an anyphylactic reaction. Other common side effects were upper respiratory tract infections.
Helpful Resources
Patient Support
Briumvi Website
Sage Treatment Tips
Before you attend your first appointment at Sage Infusion, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices, Patient Rights and Responsibilities, and Appointment Lateness and Cancelation are for reference only. Please contact us if you have any questions!
Patient Consent Form
HIPAA Privacy Authorization Form
Notice of Privacy Practices
Patient Rights and Responsibilities
Appointment Lateness and Cancelation
Find a Sage Infusion Location Near You
We offer expert infusion therapy without the hassle or cost of the hospital. We employ highly trained medical staff that work with health insurance companies & physicians to provide our patients with convenient care.
SEARCH BY ZIP
Brandon See Location
Clearwater See Location
Fort Myers See Location
Ocala Coming Soon See Location
Orlando See Location
Sarasota See Location
St. Petersburg Coming Soon See Location
Tampa See Location
The Villages Lake Sumter See Location
The Villages Spanish Springs See Location